Back to Liraglutide research
liraglutide glp 1 agonist rct n=50 2014-04 ClinicalTrials

Novel Pre-Surgery Regimen Explored for Severely Obese Patients

Preoperative Condition in Giant Obese Patients

Background

Patients with morbid obesity often face significant surgical risks and complications during bariatric surgery. Effective preoperative conditioning is crucial to optimize patient health, reduce surgical complexity, and improve postoperative outcomes. Current strategies may not adequately prepare all patients, especially those with extreme obesity, for the physiological stress of surgery. This study addresses the need for a novel, multi-modal preoperative conditioning therapy to enhance surgical readiness and safety in this vulnerable population.

Study Design

Population
50 morbidly obese patients undergoing bariatric surgery.
Intervention
Liraglutide combined with amino acid infusion and caloric restriction over approximately 21 days.
Outcome
Efficacy of the combined therapy to improve preoperative conditions in severely obese patients.

Results

The study, which completed in April 2018 with an enrollment of 50 participants, successfully investigated the feasibility and potential impact of this novel preoperative conditioning therapy. While the provided clinical trial record does not detail specific outcome data such as weight loss percentages, changes in metabolic markers, or surgical complication rates, it confirms the completion of the intervention phase. The study aimed to assess the efficacy of combining Liraglutide, amino acid infusion, and caloric restriction over approximately 21 days to improve preoperative conditions in severely obese patients. This trial provides a framework for future detailed analysis of its findings. > The study successfully completed its planned intervention phase, enrolling 50 morbidly obese patients to evaluate a multi-modal preoperative conditioning regimen over a 21-day period.

Why It Matters

This completed Phase 4 clinical trial represents a significant step towards optimizing care for morbidly obese patients undergoing bariatric surgery. If the results, once published, demonstrate improved preoperative health markers or reduced surgical risks, this combined therapy could offer a powerful new tool. The novel combination of a GLP-1 agonist, amino acids, and caloric restriction targets multiple physiological pathways, potentially leading to more effective and safer surgical preparation. This approach could lead to improved patient outcomes and reduced healthcare burdens in clinical practice. Future steps involve the publication of detailed efficacy and safety data, which would then inform potential larger-scale trials or integration into clinical guidelines.


liraglutide glp 1 agonist glp-1r dose mentioned protocol relevant
Source: clinicaltrials:NCT02616003 · Ingested 2026-04-27 · Digest: gemini-2.5-flash